Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 12, 2013, Pages

  Gurusamy, Kurinchi Selvan ^a   Tsochatzis, Emmanuel ^b   Toon, Clare D ^c   Xirouchakis, Elias ^d   Burroughs, Andrew K ^e   Davidson, Brian R ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c WEST SUSSEX COUNTY COUNCIL   (United Kingdom)

^d P Faliro Hospital   (Greece)

^e ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; INTERFERON; PEGINTERFERON; PLACEBO; RIBAVIRIN; ALPHA INTERFERON; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS; CHRONIC HEPATITIS C; CLINICAL OUTCOME; COMBINATION DRUG THERAPY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; DRUG DOSE COMPARISON; FOLLOW UP; GRAFT REJECTION; HEPATITIS C; HUMAN; LIVER FIBROSIS; LIVER GRAFT; LIVER TRANSPLANTATION; LONG TERM CARE; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; REOPERATION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; DRUG COMBINATION; GENETICS; GENOTYPE; HEPATITIS C VIRUS; LIVER CIRRHOSIS; META ANALYSIS; METHODOLOGY; RECURRENT DISEASE;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; GRAFT REJECTION; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RECURRENCE; REOPERATION; RIBAVIRIN;

EID: 84897368242     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006803.pub4     Document Type: Review

References (123)

1. Aguilera V, Prieto M, Rubin A, Risalde B, Ortiz C, Gimenez M, et al.Prospective randomized trial comparing pegIFNalpha 2a and pegIFN alpha 2b with ribavirin in HCV-liver transplant recipients with recurrent hepatitis C. American Journal of Transplantation 2011;11(Suppl S2):275.
2. Aguilera V, Prieto M, Rubin A, Risalde B, Ortiz Canto C, Berenguer M. Prospective randomized trial comparing pegIFN alpha 2A and pegIFN alpha 2B with ribavirin in HCV-liver transplant recipients with recurrent hepatitis C. Journal of Hepatology 2010;52(Suppl 1):S184.
3. Ortiz C, Lopez-Labrador FX, Canada R, Risalde B, Aguilera V, Prieto M, et al.Prospective randomized study of antiviral therapy post-transplantation: Effect of the type of Pegylated IFN and baseline immunosuppression. Liver Transplantation 2009;15(Suppl S7):S130.
4. Angelico M, Petrolati A, Lionetti R, Lenci I, Burra P, Donato MF, et al.A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. Journal of Hepatology 2007;46(6):1009-17.
5. Petrolati A, Lionetti R, Donato F, Merli M, Burra P, Angeli P, et al.Peg-interferon A-2A (40KD) with or without ribavirin in the treatment of naive patients with recurrent hepatitis C after liver transplantation. Liver Transplantation 2006;12(5):C-113.
6. Petrolati A, Lionetti R, Donato F, Merli M, Burra P, Angeli P, et al.Peginterferon alfa-2a (40KD) with or without ribavirin in the treatment of recurrent hepatitis C after liver transplantation: Preliminary report of a randomized study [EASL abstract]. Journal of Hepatology 2004;40(Suppl 1):38.
7. Petrolati A, Lionetti R, Lenci I, Paolo DD, Donato F, Merli M, et al.Peg-interferon A-2A (40KD) with or without ribavirin in the treatment of naive patients with recurrent hepatitis C after liver transplantation. Hepatology 2005;42(4 Suppl 1):482A.
8. Belli L, Volpes R, Graziadei I, Starkel P, Burroughs A, Burra P, et al.PEG-IFN-alfa 2b with ribavirin for the treatment of mild-moderate recurrent hepatitis C after liver transplantation (LT): Impact on fibrosis progression. A multicenter randomized controlled study. Hepatology 2009;50(4 Suppl):394a.
9. Belli LS, Volpes R, Graziadei I, Fagiuoli S, Starkel P, Burra P, et al.Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study. Digestive and Liver Disease 2012;44(7):603-9.
10. Calmus Y, Duvoux C, Pageaux G, Wolf P, Rostaing L, Vanlemmens C, et al.Treatment of recurrent HCV infection following liver transplantation: Results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of pegIFNalpha-2a plus ribavirin. Journal of Hepatology 2012;57(3):564-71.
11. Carrion JA, Garcia-Retortillo M, Navasa M, Rimola A, Garcia-Valdecasas JC, Forns X. Efficacy and safety of antiviral therapy in liver transplant recipients with chronic hepatitis C. Journal of Hepatology 2005;42(Suppl 2):47-8.
12. Carrion JA, Navasa M, Garcia-Retortillo M, Garcia-Pagan JC, Crespo G, Bruguera M, et al.Efficacy of antiviral therapy on disease progression in hepatitis C recurrence after liver transplantation: A randomized controlled study. Journal of Hepatology 2007;46(Suppl 1):S39-40.
13. Carrion JA, Navasa M, Garcia-Retortillo M, Garcia-Pagan JC, Crespo G, Bruguera M, et al.Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: A randomized controlled study. Gastroenterology 2007;132(5):1746-56.
14. Alpert E, Levy GA, Marotta P, Deschenes M, Yoshida E, Peck-Radosavljevic M, et al.Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology 2005;42(2):506.
15. Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, et al.Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology 2005;41(2):289-98.
16. Ferenci P, Peck-Radosavljevic M, Vogel W, Graziadei I, Riely C, Voigt MD, et al.40 KDA Peginterferon Alfa-2A (PEGASYS) in post-liver transplant recipients with established recurrent hepatitis C: Preliminary results of a randomized multicenter trial (abstract). Hepatology 2001;34(4 Pt 2):406A.
17. Vogel W, Ferenci P, Fontana R, Arbor A, Saab S, LaBrecque D, et al.Peginterferon alfa-2A (40 kd) (PEGASYS) in liver transplant recipients with established recurrent hepatitis C: Interim results of an ongoing randomized multicenter trial [abstract]. Hepatology 2002;36(4 Pt 2):312A.
18. Cotler SJ, Ganger DR, Kaur S, Rosenblate H, Jakate S, Sullivan DG, et al.Daily interferon therapy for hepatitis C virus infection in liver transplant recipients. Transplantation 2001;71(2):261-6.
19. Cotler SJ, Ganger DR, Kaur S, Rosenblate H, Jakate S, Sullivan DG, et al.Daily interferon therapy for the treatment of hepatitis C infection in liver transplant recipients [abstract]. Hepatology 1999;30(4 Pt 2):246A.
20. Crippin JS, Huang KS, Wright TL, Terrault N, Lucey ML, Poterucha J, et al.Efficacy of interferon alpha 2A (roferon-A) in the treatment of hepatitis C and G following liver transplantation: A prospective, randomized study [AASLD abstract]. Hepatology 1996;24(4 Pt 2):294A.
21. Gane EJ, Lo SK, Portmann B, Lau JYN, Naoumov NN, Williams R. A randomised study of the safety and efficacy of ribavirin vs interferon monotherapy for recurrent HCV infection in liver transplant recipients. Hepatology 1996;24(4 Pt 2):293A.
22. Gane EJ, Lo SK, Riordan SM, Portmann BC, Lau JY, Naoumov NV, et al.A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998;27(5):1403-7.
23. Gane E, Strasser SI, Crawford D, Ring J, Rizkalla B, Thompson S, et al.Combination therapy is superior to pegylated interferon monotherapy for the treatment of recurrent hepatitis C. Journal of Gastroenterology and Hepatology 2009;24(Suppl S2):A278.
24. Gane EJ, Strasser SI, Crawford DH, Ring JA, Rizkalla B, Thompson SJ, et al.A multicenter, randomized trial of combination pegylated interferon-alpha 2a plus ribavirin vs. pegylated interferon-alpha 2A monotherapy in liver transplant recipients with recurrent hepatitis C. Hepatology 2009;50(Suppl 4):393A-394A.
25. Ghalib R, Pandula R, Kadhim TJ, Clark C, Ankoma-Sey V, Fouzia S, et al.Treatment of recurrent hepatitis C after liver transplantation with alpha-2B interferon plus ribavirin. Hepatology 2000;32(4 Pt 2):291A.
26. Ghalib R, Levine C, Hollinger B, Stribling R, Box T, Huston W, et al.Treatment of recurrent hepatitis C after liver transplantation. Liver Transplantation 2006;12(5):C-29.
27. Ghalib R, Levine C, Hollinger B, Stribling R, Box T, Hutson W, et al.Increased LFTS/clinical liver failure in post OLT patients being treated with peg-IFN alfa-2b plus ribavirin for recurrent hepatitis C. Liver Transplantation 2009;15(Suppl S7):S186.
28. Ghalib R, Levine C, Hollinger B, Stribling R, Box T, Hutson W, et al.Sustained viral response using peg-inf alfa-2B plus ribavirin in patients with recurrent hepatitis C after liver transplantation. Hepatology 2006;44(4 Suppl 1):478A.
29. Ghalib R, Levine C, McClelland T, Hollinger B, Stribling R, Box T, et al.Factors predictive of 24 week viral response to peg IFN alfa-2B plus ribavirin in patients with recurrent hepatitis C after liver transplantation. Hepatology 2004;40(4 Suppl 1):358A.
30. Ghalib RH, Levine CD, Hollinger FB, Stribling R, Box TD, Hutson W, et al.Increased LFTS/clinical liver failure in post OLT patients being treated with pegIFN alfa-2B plus ribavirin for recurrent hepatitis C. Gastroenterology 2009;5(Suppl 1):A811-2.
31. Gordon FD, Morin D, Davis C, Trabucco A, Simpson MA, Pomposelli JJ, et al.High sustained virological response (SVR) in HCV treatment with peginterferon-alfa 2b (PEG) and ribavirin (RBV) after liver transplantation (LT). American Journal of Transplantation 2005;5(S11):181.
32. Lodato F, Berardi S, Gramenzi A, Mazzella G, Lenzi M, Morelli MC, et al.Clinical trial: Peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation. Alimentary Pharmacology and Therapeutics 2008;28(4):450-7.
33. Nair S, Lipscomb J, Eason J. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation. Transplantation 2008; Vol. 86, issue 3:418-22. [0041-1337]
34. Nair S, Lipscomb J, Malloy H, Loss G, Cohen A, Eason J. Treatment of recurrent hepatitis C infection after liver transplantation: Randomized controlled trial of peg interferon alpha 2b and ribavirin vs. peg interferon alpha 2b, ribavirin and amantadine. Gastroenterology 2004;126(4 Suppl 2):A699.
35. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SNS, Lemonnier C, et al.Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology 2003;124(3):642-50.
36. Samuel D, Bizollon T, Feray C, Roche B, Lemonnier C, Plough S, et al.Combination of interferon alfa 2-B plus ribavirin for recurrent HCV infection after liver transplantation: A randomized controlled study. Hepatology 2000;32(4 Pt 2):295A.
37. Yedibela S, Demir R, Melling N, Aydin U, Schuppan D, Muller V, et al.Antiviral re-treatment of IFN-ribavirin non-responders for recurrent post-transplantation hepatitis C. Clinical Transplantation 2011;25(1):131-5.
38. Beckebaum S, Cicinnati VR, Karliova M, Dirsch O, Erim Y, Frilling A, et al.Daily interferon alpha-2B and ribavirin combination therapy for liver transplant patients with chronic hepatitis C infection. Transplantation Proceedings 2003;35(6):2080-1.
39. Beckebaum S, Cicinnati VR, Zhang X, Malago M, Dirsch O, Erim Y, et al.Combination therapy with peginterferon alpha-2B and ribavirin in liver transplant recipients with recurrent HCV infection: Preliminary results of an open prospective study. Transplantation Proceedings 2004;36(5):1489-91.
40. Boillot O, Berger F, Rasolofo E, Mion F, Chevallier P, Gille D, et al.Effects of early interferon alfa therapy for hepatitis C virus infection recurrence after liver transplantation. Transplantation Proceedings 1995;27(4):2501.
41. Casanovas TT, Casais ALA, Samuel D, Bizollon T, Trepo C. Chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology 2004;126(1):373-4.
42. Castedal M, Siewert DA, Olausson M, Friman S. Combination therapy of interferon alpha-2B and ribavirin for recurrent hepatitis C after liver transplantation. Transplantation Proceedings 2003;35(2):820-1.
43. Catalano G, Urbani L, Oliveri F, Iaria G, Biancofiore G, Mosca F, et al.Recurrence of hepatitis C in liver transplants from elderly donors aged more than 75 years. Transplantation Proceedings 2003;35(3):1034.
44. Ceccherini NL, Giannotti A, Malizia T, Ciccorossi P, Olivieri F, Vanni M, et al.Recurrence of HCV infection in liver transplant patients: Evaluation of IgM anti-HCV and IgM anti-CMV. Transplantation Proceedings 2003;35(3):1030-1.
45. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transplantation 2002;8(4):350-5.
46. Dumortier J, Scoazec JY, Berger F, Boillot O. Recurrence of hepatitis C after liver transplantation: Follow-up and treatment. Transplantation Proceedings 2002;34(3):779-81.
47. Calmus Y, Duvoux C, Samuel D, Pageaux GP, Messner M, Wolf P, et al.Multicenter randomized trial of HCV treatment with peginterferon-alfa 2a and ribavirin after liver transplantation: One-year report. Hepatology 2005;42(4 Suppl 1):487A.
48. Calmus Y, Samuel D, Pageaux G, Messner M, Wolf P, Rostaing L, et al.Multicenter randomized trial in HCV-Infected patients treated with peginterferon alfa-2a and ribavirin followed by ribavirin alone after liver transplantation (TRANSPEG): Role of erythropoietin (Epo) on viral response. American Journal of Transplantation 2007;7(Suppl 2):372.
49. Calmus Y, Samuel D, Pageaux G, Messner M, Wolf P, Rostaing L, et al.Multicenter randomized trial in HCV-infected patients treated with peginterferon alfa-2A and ribavirin followed by ribavirin alone after liver transplantation: 18-month report. Hepatology 2006;44(4 Suppl 1):189A.
50. Duvoux C, Samuel D, Pageaux G, Messner M, Wolf P, Rostaing L, et al.Multicenter randomized trial of HCV treatment with peginterferon-alpha 2a and ribavirin in liver transplant patients with established recurrent hepatitis C: Interim analysis. Journal of Hepatology 2006;44(Suppl 2):S3.
51. Fontana M, Ciuffreda D, Moradpour D, Pascual M. Combined antiviral therapy for recurrent hepatitis C virus after liver transplantation. Transplantation 2007;83(4):525-6.
52. Israeli E, Galun E, Eid A, Ilan Y, Ashur Y, Jurim O, et al.Combination therapy for hepatitis C virus reinfection after orthoptic liver transplantation. Transplantation Proceedings 2001;33(6):2929.
53. Kizilisik TA, al-Sebayel M, Hammad A, al-Traif I, Ramirez CG, Abdulla A. Hepatitis C recurrence in liver transplant recipients. Transplantation Proceedings 1997;29(7):2875-7.
54. Pinna AD, Ricordi C, Weppler D, Ruiz P, Tzakis AG. Treatment of recurrent hepatitis C after liver transplantation with IL-2r Ab. Transplantation Proceedings 2001;33(1-2):1087-9.
55. Samuel D, Roche B, Feray C. Treatment of hepatitis C virus infection after liver transplantation. Gastroenterologie Clinique et Biologique 2002;26(Spec 2):B231-7.
56. Samuel D, Bizollon T, Trepo C. Chronic hepatitis C after liver transplantation: A randomized study - Reply. Gastroenterology 2004;126(1):373-4.
57. Samuel D. Antiviral treatment of recurrent hepatitis C after liver transplantation: The need for a multifaceted approach. Hepatology 2005;41(3):436-8.
58. Samuel D, Roche B. Ribavirin in the treatment of recurrent hepatitis C after liver transplantation: Difficult to manage but essential for success. Journal of Hepatology 2007;46(6):988-91.
59. Shakil O, Rakela J. Interferon-alfa2B and ribavirin combination therapy in liver transplant recipients with recurrent hepatitis C A [abstract]. Hepatology 1999;30(4 Pt 2):656A.
60. Shakil AO, Habib S, Berk B, Eghtesad B, Marcos A, Fung JJ. A trial of pegylated interferon and ribavirin among liver transplant recipients with hepatitis C: Reasons for screening failure and low enrollment. Hepatology 2004;40(4 Suppl 1):360A.
61. Taltavull TC, Alvarez LAC. Chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology 2004;126(1):373.
62. Targhetta S, Burra P, Popovic A, Silverj E, Pevere S, Russo FP, et al.Natural alpha-IFN in HCV recurrence after liver transplantation. Transplantation Proceedings 2001;33(1-2):1457-8. [0041-1345: (Print)]
63. Testino G, Sumberaz A, Ravetti G, Gentile R, Ansaldi F, Icardi G. Pegylated interferon (PEG-IFN) alfa-2b and ribavirin for recurrent hepatitis C (genotype 1) after liver transplantation: Relationship with steatosis. Digestive Liver Diseases 2006;38(11):864-5.
64. Vargas V, Charco R, Castells L, Esteban R, Margarit C. Alpha-interferon for acute hepatitis C in liver transplant patients. Transplantation Proceedings 1995;27(1):1222-3.
65. Wietzke P, Braun F, Ringe B, Ramadori G. Interferon alfa-2A and ribavirin therapy for hepatitis C recurrence after liver transplantation. Transplantation Proceedings 2000;32(7):2539-42.
66. Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, et al.Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study. Gastroenterology 2004;126(5):1302-11.
67. Arjal RR, Burton JR Jr, Villamil F, Rosen HR. Review article: The treatment of hepatitis C virus recurrence after liver transplantation. Alimentary Pharmacology and Therapeutics 2007;26(2):127-40.
68. Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, Netto G, et al.A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003;38(1):34-41.
69. Bombuy E, Fondevila C, Rodriguez-Laiz G, Ferrer J, Amador A, Valentini M, et al.Ischemic preconditioning in adult living donor liver transplantation, a pilot study [EASL abstract]. Journal of Hepatology 2004;40(Suppl 1):39.
70. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61:763-9.
71. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive - Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98.
72. Cameron AM, Ghobrial RM, Hiatt JR, Carmody IC, Gordon SA, Farmer DG, et al.Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Annals of Surgery 2006;244(4):563-71.
73. Cescon M, Grazi GL, Grassi A, Ravaioli M, Vetrone G, Ercolani G, et al.Effect of ischemic preconditioning in whole liver transplantation from deceased donors. A pilot study. Liver Transplantation 2006;12(4):628-35.
74. The CONSORT Group. Transparent reporting of trials, 2009. www.consort-statement.org/equator-network-news-feb-2009/ (accessed on 18 November 2013).
75. Corno V, Colledan M, Dezza MC, Guizzetti M, Lucianetti A, Maldini G, et al.Extended right split liver graft for primary transplantation in children and adults. Transplantation International 2006;19(6):492-9.
76. Copenhagen Trial Unit. TSA - trial sequential analysis, 2011. ctu.dk/tsa/ (accessed 18 November 2013).
77. DeMets DL. Methods for combining randomized clinical trials: Strengths and limitations. Statistics in Medicine 1987;6(3):341-50.
78. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
79. Dieterich DT, Wasserman R, Brau N, Hassanein TI, Bini EJ, Bowers PJ, et al.Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. American Journal of Gastroenterology 2003;98(11):2491-9.
80. Eason JD, Loss GE, Blazek J, Nair S, Mason AL. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: Results of a prospective randomized trial. Liver Transplantation 2001;7(8):693-7.
81. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34.
82. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122(4):889-96.
83. Ghobrial RM, Farmer DG, Baquerizo A, Colquhoun S, Rosen HR, Yersiz H, et al.Orthotopic liver transplantation for hepatitis C: Outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Annals of Surgery 1999;229(6):824-31; discussion 831-3.
84. Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al.Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 9. Art. No.: LIVER.
85. Gurusamy KS, Gluud C, Nikolova D, Davidson BR. Assessment of risk of bias in randomized clinical trials in surgery. British Journal of Surgery 2009;96(4):342-9. [PUBMED: 19283747]
86. Gurusamy KS, Tsochatzis E, Toon C, Davidson BR, Burroughs AK. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation. Cochrane Database of Systematic Reviews 2013, issue Under editorial. [DOI: 10.1002/14651858.CD006573.pub3]
87. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
88. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
89. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
90. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, PA 19063-2043, USA: Barnett International/PAREXEL, 1997.
91. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
92. Koneru B, Fisher A, He Y, Klein KM, Skurnick J, Wilson DJ, et al.Ischemic preconditioning in deceased donor liver transplantation: A prospective randomized clinical trial of safety and efficacy. Liver Transplantation 2005;11(2):196-202.
93. Lim SG, Wai CT, Da Costa M, Sutedja DS, Lee YM, Lee KH, et al.Referral patterns and waiting times for liver transplantation in Singapore. Singapore Medical Journal 2006;47(7):599-603.
94. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2]
95. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Statistics in Medicine 2001;20(4):641-54.
96. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
97. Newell DJ. Intention-to-treat analysis: Implications for quantitative and qualitative research. International Journal of Epidemiology 1992;21(5):837-41.
98. NHS Blood and Transplant - Organ Donation and Transplantation 2012-2013. http://www.organdonation.nhs.uk/statistics/transplant_activity_report/current_activity_reports/ukt/activity_report_2012_13.pdf (accessed 20 November 2013).
99. The Organ Procurement and Transplant Network/Scientific Registry of Transplant Recipients. OPTN/SRTR 2009 annual report, 2009. www.ustransplant.org/annual_reports/current/905_li.pdf (accessed 18 November 2013).
100. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34. [PUBMED: 9921604]
101. Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, et al.Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. Journal of Hepatology 2007;46(3):459-65.
102. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
103. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
104. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: Rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
105. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al.Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
106. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al.Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
107. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
108. Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, et al.Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transplantation 2007;13(8):1100-8.
109. Sharvadze L, Tsertsvadze T, Gochitashvili N, Kakabadze T, Dolmazashvili E. Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C. Georgian Medical News 2006;137:62-5.
110. Sharvadze L, Gochitashvili N, Tophuria A, Bolokadze N, Tsertsvadze T. IFN/RBV treatment induced neutropenia and its correction with neupogen in patients with hepatitis C. Georgian Medical News 2007;147:52-5.
111. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al.SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Annals of Internal Medicine 2013;158:200-7.
112. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, et al.SPIRIT 2013 explanation and elaboration: Guidance for protocols of clinical trials. BMJ (Clinical Research Ed.) 2013;346:e7586.
113. StatsDirect Ltd. StatsDirect Statistical software Version 2.7.7. StatsDirect Ltd, 2009.
114. Sugo H, Balderson GA, Crawford DH, Fawcett J, Lynch SV, Strong RW, et al.The influence of viral genotypes and rejection episodes on the recurrence of hepatitis C after liver transplantation. Surgery Today 2003;33(6):421-5.
115. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al.Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses. International Journal of Epidemiology 2009;38(1):276-86.
116. Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology 2010;2:57-66.
117. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA), 2011. ctu.dk/tsa/files/tsa_manual.pdf (accessed 18 November 2013).
118. Triantos C, Samonakis D, Stigliano R, Thalheimer U, Patch D, Burroughs A. Liver transplantation and hepatitis C virus: Systematic review of antiviral therapy. Transplantation 2005;79(3):261-8.
119. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
120. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology 2009;9:86.
121. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al.Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: Meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-5.
122. Gurusamy KS, Osmani B, Xirouchakis E, Burroughs AK, Davidson BR. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD006803.pub2]
123. Gurusamy KS, Tsochatzis E, Xirouchakis E, Burroughs AK, Davidson BR. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD006803.pub3]